Targeted Therapy | Novartis

Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021

Basel, November 08, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced new analyses from the two-year positive Phase III JUNIPERA study, which demonstrated the treatment response of Cosentyx® (secukinumab) in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) –…

Targeted TherapyReimagine MedicineChronic Illness
Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients

Basel, September 29, 2021 — Novartis, a leader in immuno-dermatology and rheumatology, today announced new analysis from a Phase IIb study demonstrating the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients1. Complete control of symptoms…

Targeted TherapyReimagine MedicineMedical Innovations
New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis

Basel, September 29, 2021 — Novartis, a leader in immuno-dermatology and rheumatology, today announced data from an international Phase IIIb study, which showed treatment with Cosentyx® (secukinumab) 300 mg in a 2 mL autoinjector (UnoReady® pen) resulted in high efficacy and convenient administration in adults with moderate to severe plaque…

Targeted TherapyReimagine MedicineMedical Innovations
Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria

Basel, September 30, 2021 — Novartis today announced positive Phase IIb data showing remibrutinib (LOU064), a potentially best-in-class oral BTK inhibitor, demonstrated rapid and effective disease control in patients with inadequately controlled chronic spontaneous urticaria (CSU). The data were presented as a late-breaking abstract at the …

Targeted TherapyReimagine MedicineMedical Innovations
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Basel, December 9, 2019 – Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications. These analyses are from a readout of a 15-year post-marketing study that add to and complement the rigor of the Kymriah pivotal trials with…

Targeted TherapyReimagine MedicineCell and Gene TherapyCancer
Novartis completes tender offer for all outstanding shares of The Medicines Company

Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), for all of the outstanding shares of common stock, par value USD 0.001 per share, of The Medicines Company (NASDAQ: MDCO…

Targeted TherapyInnovationHeart FailureChronic IllnessAd Hoc
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that it has completed the acquisition of The Medicines Company (the “Company”) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), with and into the Company, with the Company surviving the merger, without…

Targeted TherapyInnovationHeart FailureChronic Illness
Patient Perspectives

Your Genes, Your Melanoma

Learn about the role of precision oncology in advanced melanoma treatment.

CancerDisease AwarenessLiving With DiseaseOncologyPatient EducationTargeted TherapyGene Testing
Patient Perspectives

Meet T.J. Sharpe

Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.

CancerOncologyPatient VoicesSocial CommitmentTargeted TherapyClinical Trials
Access to Healthcare

Talking to: Ann Aerts, Head of the Novartis Foundation

With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.

Novartis AccessPatient EducationTargeted Therapy
From Our Labs

Turning the power of nuclear technology into a medical force

Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.

CancerOncologyTargeted TherapyDrug DevelopmentDrug Design
Discovery

Rare speed on a rare disease

An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.

Novartis Institutes for BioMedical ResearchRare DiseasesReimagine MedicineTargeted TherapyClinical ResearchClinical TrialsGenetic Disease